Department of Surgery, Division of Surgical Oncology, Duke University Medical Center, Durham, NC 27710, United States.
Department of Pharmacology, The Pennsylvania State University College of Medicine, Hershey, PA 17033, United States.
Biotechnol Adv. 2016 Sep-Oct;34(5):565-577. doi: 10.1016/j.biotechadv.2016.01.004. Epub 2016 Jan 28.
Drug toxicity and resistance remain formidable challenges in cancer treatment and represent an area of increasing attention in the case of melanoma. Nanotechnology represents a paradigm-shifting field with the potential to mitigate drug resistance while improving drug delivery and minimizing toxicity. Recent clinical and pre-clinical studies have demonstrated how a diverse array of nanoparticles may be harnessed to circumvent known mechanisms of drug resistance in melanoma to improve therapeutic efficacy. In this review, we discuss known mechanisms of resistance to various melanoma therapies and possible nanotechnology-based strategies that could be used to overcome these barriers and improve the pharmacologic arsenal available to combat advanced stage melanoma.
药物毒性和耐药性仍然是癌症治疗中的严峻挑战，在黑色素瘤的情况下，这是一个日益受到关注的领域。纳米技术是一个具有变革性的领域，有可能减轻耐药性，同时改善药物传递并最小化毒性。最近的临床前和临床研究表明，如何利用各种纳米粒子来规避黑色素瘤中已知的耐药机制，以提高治疗效果。在这篇综述中，我们讨论了各种黑色素瘤疗法耐药的已知机制，以及可能用于克服这些障碍并改善现有药物库以对抗晚期黑色素瘤的基于纳米技术的策略。
